Roche is a Swiss multinational healthcare company headquartered in Basel, Switzerland, with significant neuroscience R&D programs.
[1]
| Attribute | Value |
|-----------|-------|
| Ticker | SIX: RO, OTC: RHHBY |
| Founded | 1896 |
| Headquarters | Basel, Switzerland |
| CEO | Thomas Schinecker |
| Market Cap | ~$260B (2026) |
- Mechanism: Monoclonal antibody targeting amyloid plaques
- Target: Aβ fibrils and plaques
- Status: Withdrawn from FDA review (2024)
- Trial: GRADUATE I & II Phase 3
- Note: Showed amyloid removal but insufficient clinical efficacy
- Mechanism: Monoclonal antibody targeting Aβ monomers and oligomers
- Target: Aβ oligomers
- Status: Failed Phase 3 (CREAD)
- Trial: CREAD Phase 3 (terminated for futility)
- Mechanism: Brain-penetrant anti-Aβ antibody
- Target: Amyloid plaques
- Status: Phase 2
- Mechanism: α-Synuclein aggregation inhibitor
- Target: α-Synuclein
- Status: Phase 1
- Anti-α-Syn antibody — Discovery stage
- Mechanism: Anti-α-synuclein monoclonal antibody
- Target: Alpha-synuclein pathology
- Status: Phase 2 (AMBAR study)
- Indication: Multiple System Atrophy
- Note: Results from AMBAR study published in Lancet Neurology 2025 showing efficacy
- Partnership: Developed with Genentech
| Year |
Revenue |
Key Products |
| 2025 |
CHF 68B |
Ocrevus, Hemlibra, Tecentriq |
| 2024 |
CHF 62B |
Ocrevus, Hemlibra, Avastin |
- IPO: 2000 (SIX: RO)
- Market Cap: ~$260B (2026)
- 2025 Revenue: CHF 68B (~5B)
- 2024 Revenue: CHF 62B
- R&D Investment: ~$15B annually
- Dividend: CHF 2.70 per share (2025)
- Genentech: US commercialization (subsidiary)
- AC Immune: Tau and α-Syn programs
Roche, in partnership with Neurocrine Biosciences, is developing an AAV-based gene therapy for Dravet syndrome caused by loss-of-function variants in SCN1A.
- Mechanism: AAV-delivered full-length SCN1A gene replacement
- Target: SCN1A (Nav1.1 sodium channel, ~6 kb coding sequence)
- Technical approach: Addressing the AAV packaging constraint through optimized construct design
- Stage: IND-enabling (March 2026)
- Partner: Neurocrine Biosciences (NASDAQ: NBIX)
Competitive landscape: The program competes with Stoke Therapeutics ASO (STK-001, Phase 2) and Encoded Therapeutics AAV CRISPRa (ETX101, Phase 1).
Roche and Neurocrine are also developing a KCNQ2/KCNQ3 potassium channel opener program for focal onset seizures.
- Mechanism: Enhances M-current (Kv7.2/Kv7.3 channels) to stabilize neuronal excitability
- Stage: Phase 1
Roche has a significant investment in neuroscience research, with multiple programs in clinical development for Alzheimer's disease, Parkinson's disease, and other neurological disorders.
Crenezumab (MABT5102A)
Anti-amyloid beta monoclonal antibody.
- Phase II ACCORD: Results showed reduced amyloid but not clinical benefit
- Partnership: Genentech (Roche subsidiary)
Anti-tau antibodies: Multiple programs in various stages
SOD1 inhibitors: For ALS (in partnership)
- GBA program: Gene therapy approaches
- LRRK2 inhibitors: Early discovery
- Alpha-synuclein aggregation inhibitors: Preclinical
Ocrelizumab (Ocrevus): CD20 antibody for MS
- Approved: 2017 for relapsing and primary progressive MS
- Mechanism: B-cell depletion
- Market: >B annually
Evrysdi (risdiplam): SMN2 splicing modifier
- Approved: 2020 for SMA
- First oral treatment for SMA
- Partnership: PTC Therapeutics (Roche has rights)
Roche's diagnostics business is a key differentiator:
- Cerebral spinal fluid (CSF) biomarkers: p-tau, Aβ42
- Blood-based biomarkers: p-Tau181, p-Tau217
- Neuroimaging AI: Partnership for amyloid PET analysis
- Founded: 1896
- Headquarters: Basel, Switzerland
- SIX Swiss Exchange: ROG
- Market Cap: ~80B (as of 2026)
- 2025 Revenue: ~8B (pharmaceuticals + diagnostics)
- MabThera/Rituxan: Anti-CD20, cancer and autoimmune
- Avastin: Anti-VEGF, cancer
- Herceptin: Anti-HER2, breast cancer
- Hemlibra: Factor VIII mimetic, hemophilia A
- AC Immune: Tau and amyloid partnerships
- Prothelia: Muscular dystrophy
- GeNeuro: MS partnerships
- Academic collaborations: Multiple university partnerships worldwide